Bicara Therapeutics Inc. Common Stock

NASDAQ:BCAX

Biotechnology

Healthcare
$9.38 +0.00%

+$0.00 today

Market cap
$622.71M
Beta
-0.53
P/E (TTM)
-8.8
EPS (TTM)
-$2.59
52W Low $8.48High $24.25

Volume 1.30M

Average 0.54M

BCAX Operating Income

Profit from core operations after operating expenses, before interest and taxes.

Bicara Therapeutics Inc. Common StockNASDAQ: BCAX

Operating Income · Q1 FY2026 · quarter ended Mar 2026

Operating income remains negative

Q1 FY2026 operating income was -$60.24M, compared with -$41.79M a year earlier. Trailing-twelve-month operating income was -$174.06M.

Context

  • Operating income grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether operating income reaches the consensus estimate of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -88.9% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$60.24M-46.5% QoQ
Last fiscal yearDec 2025
-$155.6M-88.9% YoY
LTMMar 2026
-$174.06M-60.0% YoY
Operating Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-44.2%+100.0%+144.2 pp
1 year-88.9%+100.0%+188.9 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Income history

USD · from the income statement

Latest · FY2025
(155.6M) USD
Year-over-year change
-88.9%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Income vs competitors

How BCAX compares with its peers on the latest reported figures

  • BCAX's LTM Mar 2026 operating income of -$174.06M is the 5th highest of the 6 companies compared; the peer median is -$75.17M.
  • Its year-over-year change of -60.0% is the 5th highest of 6, against a peer median of -21.6%.
BCAX Competitors Peer median
Operating Income for BCAX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CNTXContext Therapeutics Inc.LTM Mar 2026-$43.52M -37.6%——
MGNXMacroGenics, Inc.LTM Mar 2026-$63.66M +36.0%—40.5%
CMPXCompass Therapeutics, Inc.LTM Mar 2026-$75.17M -21.6%——
CBIOCrescent Biopharma, Inc.LTM Mar 2026-$163.14M -207.8%—1372.9%
BCAXBicara Therapeutics Inc. Common StockLTM Mar 2026-$174.06M -60.0%——
CGEMCullinan Therapeutics, Inc.LTM Mar 2026-$240.35M -15.0%——
VRXAVeraxa Biotech Holding AG—— ———
Peer median (excluding BCAX) -$75.17M-21.6%—706.7%

Competitors are the stored peer set for BCAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0000
Cost of Revenue0000
Gross Profit0000
Gross Margin————
Research & Development31.31M30.62M63.62M125.1M
Selling, General & Admin6.34M9.27M18.77M30.51M
Operating Expenses37.66M39.89M82.39M155.6M
Depreciation & Amortization10K19K56K105K
EBITDA(37.72M)(51.96M)(67.75M)(137.63M)
EBITDA Margin————
Operating Income(37.66M)(39.89M)(82.39M)(155.6M)
Operating Margin————
Interest Income4K1.31M14.58M17.87M
Interest Expense112K000
Other Income / Expenses(188K)(12.09M)14.58M17.87M
Income Before Tax(37.84M)(51.98M)(67.81M)(137.73M)
Pre-Tax Margin————
Income Tax Expense1K5K187K217K
Net Income(37.85M)(51.99M)(68M)(137.95M)
Net Margin————
EPS (Basic)(0.73)(1.00)(1.25)(2.52)
EPS (Diluted)(0.73)(1.00)(1.25)(2.52)
Weighted Avg Shares51.76M51.76M54.42M54.68M
Weighted Avg Shares (Diluted)51.76M51.76M54.42M54.68M

Bicara Therapeutics Inc. Common Stock

NASDAQ:BCAX

Intrinsic Alpha fair value

Locked

Current Price

$9.38

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.